Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECIPHER trial of dapagliflozin after acute myocardial infarction
ACTRN12626000200381Phase 4Not yet recruiting
- Sponsor
- Victorian Heart Institute
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in myocardial infarction (MI) and coronary arteriosclerosis comparing Dapagliflozin plus standard of care with Standard of care alone (2 arms). Primary endpoints: Change in coronary plaque composition, Change in coronary microcalcification activity and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
myocardial infarction (MI)coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12626000200381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000200381.